Botanix Pharmaceuticals Ltd. expanded the scope of its novel delivery technology to include any drug actives that can be used for skin diseases, not just cannabinoid-based treatments.

The Permetrex technology is used as a delivery formulation for Botanix's acne treatment BTX-1503, which is undergoing clinical development.

"As many existing dermatology products use sub-optimal formulations that suffer from ... limitations, a range of marketed skin disease drugs can be substantially improved utilizing the Permetrex approach," the company said.

"Because the underlying drug active is already approved and marketed, new and improved Permetrex-enabled products can be developed quickly and commercialized without the need to submit the new products for FDA or other regulatory agency approval" Botanix executive director Matt Callahan added.